

DAFTAR PUSTAKA

1. Kemenkes RI. Infodatin HIV/AIDS. In: Kementerian Kesehatan Republik Indonesia, editor. 2020. p. 1–8.
2. Yuliyanasari N. Global Burden Disease – Human Immunodeficiency Virus – Acquired Immune Deficiency Syndrome (Hiv-Aids). Qanun [Internet]. 2017;01(October 2016):65–77.
3. Kogoya T, Demartoto A, Murti B. Survival Predictors of People Living with HIV/ AIDS in Wamena, Papua. *Indones J Med.* 2017;2(3):184–91.
4. UNAIDS. Unaid Data 2023. 2023. 1–463 p.
5. WHO. HIV Statistics, Globally and By WHO Region, 2023. World Health Organization [Internet]. 2023;1–8.
6. UNAIDS. Word AIDS Day 2023: Global HIV statistics. 2023;1–6.
7. Wang HB, Mo QH, Yang Z. HIV vaccine research: The challenge and the way forward. *J Immunol Res.* 2015;2015.
8. Direktorat Jenderal P2P. Laporan Eksekutif Perkembangan HIV AIDS dan Penyakit Infeksi Menular Seksual (PIMS) Triwulan IV Tahun 2022. 2022;1–15.
9. Seksi P2P Dinas Kesehatan Sumatera Barat. Laporan Kasus HIV AIDS di Sumatera Barat 2018-2022. 2023.
10. Direktorat Jenderal P2P. Laporan Perkembangan HIV AIDS & Penyakit Infeksi Menular Seksual (PIMS) Triwulan IV Tahun 2019. In Jakarta; 2020.
11. Kemenkes RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2015 Tentang Pedoman Pengobatan Antiretroviral. In 2015. p. 140.
12. Kemenkes RI. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK. 02.02/Menkes/482/2014.
13. Seksi Pelaporan Kunjungan VCT. Laporan Kunjungan Pengambilan Obat ODHA di RSUP Dr. M. Djamil Padang tahun 2018-2022. Annisa R, editor. 2023.
14. Seksi Monitoring dan Evaluasi Rekam Medis. Laporan Kasus HIV/AIDS di RSUP Dr. M. Djamil Padang Tahun 2018-2022. Annisa R, editor. 2023.
15. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. Third Edit. Springer Science + Business Media; 2012. 1–712 p.

16. Zhang G, Gong Y, Wang Q, Deng L, Zhang S, Liao Q, et al. Outcomes and factors associated with survival of patients with HIV/AIDS initiating antiretroviral treatment in Liangshan Prefecture, southwest of China: A retrospective cohort study from 2005 to 2013. *Med (United States)*. 2016;95(27).
17. Afrashteh S, Fararouei M, Ghaem H, Gheibi Z. Factors associated with progression from HIV to death in patients receiving antiretroviral therapy in Southern Iran: a 21-year survival analysis and follow-up study. *HIV AIDS Rev*. 2023;22(3):189–97.
18. Damtew B, Mengistie B, Alemayehu T. Survival and determinants of mortality in adult HIV/Aids patients initiating antiretroviral therapy in Somali Region, Eastern Ethiopia. *Pan Afr Med J*. 2015;22:1–8.
19. Tao Y, Xiao X, Zhang C, Xie Y, Wang H. Prevalence of delayed antiretroviral therapy initiation among people living with HIV: A systematic review and meta-analysis. *PLoS One* [Internet]. 2023;18(10 October):1–17.
20. Teka Z, Mohammed K, Workneh G, Gizaw Z. Survival of HIV/AIDS patients treated under ART follow-up at the University hospital, northwest Ethiopia. *Environ Health Prev Med*. 2021;26(1):1–9.
21. Mohammadi Y, Mirzaei M, Shirmohammadi-Khorram N, Farhadian M. Identifying risk factors for late HIV diagnosis and survival analysis of people living with HIV/AIDS in Iran (1987–2016). *BMC Infect Dis*. 2021;21(1):1–9.
22. Acharya S, Palkar A, Keskar P, Setia MS. Factors Associated with Survival in Adult People Living with HIV/AIDS (PLHAs) in Mumbai, India (2004-2019): A Retrospective Cohort Study. *J Fam Med Prim Care*. 2021;10:756–64.
23. Tesfamariam K, Baraki N, Kedir H. Pre-ART nutritional status and its association with mortality in adult patients enrolled on ART at Fiche Hospital in North Shoa, Oromia region, Ethiopia: A retrospective cohort study. *BMC Res Notes*. 2016;9(1):1–9.
24. Theresia TT. Pengaruh Jumlah CD4 Awal terhadap Kesintasan 10 Tahun Pasien HIV/AIDS di RS Kanker Dharmais Tahun 2004-2006. Universitas Indonesia; 2016.
25. Anggraeni ND. Ketahanan Hidup Satu Tahun Pasien HIV/AIDS dengan Pengobatan ARV Lini Pertama berdasarkan Jumlah CD4 Sebelum Pengobatan ARV di RSPI Prof. Dr. Sulianti Saroso Tahun 2005-2010. Universitas Indonesia; 2010.
26. Seyoum D, Degryse JM, Kifle YG, Taye A, Tadesse M, Birlie B, et al. Risk

factors for mortality among adult HIV/AIDS patients following antiretroviral therapy in southwestern ethiopia: An assessment through survival models. *Int J Environ Res Public Health*. 2017;14(3):1–12.

27. Nigussie F, Alamer A, Mengistu Z, Tachbele E. Survival and predictors of mortality among adult hiv/aids patients initiating highly active antiretroviral therapy in debre-berhan referral hospital, amhara, ethiopia: A retrospective study. *HIV/AIDS - Res Palliat Care*. 2020;12:757–68.
28. Siraj M, Gedamu S, Tegegne B. Predictors of Survival Time Among HIV-Infected Adults After Initiating Anti-Retroviral Therapy in Kombolcha Town: A 5-Year Retrospective Cohort Study. *HIV/AIDS - Res Palliat Care*. 2022;14(April):181–94.
29. Tadesse K, Haile F, Hiruy N. Predictors of mortality among patients enrolled on antiretroviral therapy in Aksum hospital, Northern Ethiopia: A retrospective cohort study. *PLoS One*. 2014;9(1).
30. Zhao Y, Wu Z, McGoogan JM, Shi CX, Li A, Dou Z, et al. Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: A nationwide, retrospective cohort study. *Clin Infect Dis*. 2018;66(5):727–34.
31. Kemenkes R. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/90/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV. Vol. 561, kemenkes. 2019. 2–3 p.
32. Hidayati AN, Rosyid AN, Nugroho CW, Asmarawati TP. Manajemen HIV/AIDS Terkini, Komprehensif, dan Multidisiplin. Surabaya: Airlangga University Press; 2019. 1–906 p.
33. Hidayat AN, Daili SF, Niode NJ, Indriatmi W, Budiono SE, Barakbah J. Manifestasi dan Tatalaksana Kelainan Kulit dan Kelamin pada Pasien HIV/AIDS. Fakultas Kedokteran Universitas Indonesia. Fakultas Kedokteran Universitas Indonesia; 2019. 1–22 p.
34. McClure M, Schulz TF. Origin of HIV/AIDS and risk for ongoing zoonotic transmissions from nonhuman primates to human virus. *BMJ Open*. 2010;298:1–2.
35. WHO. HIV and AIDS [Internet]. 2023 [cited 2023 Feb 19]. Available from: <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>
36. UNAIDS. UNAIDS Global AIDS Update 2022. 2022. 1–376 p.
37. International Labour Organization (ILO). Flipchart Pencegahan dan Penanggulangan HIV dan AIDS. Int Labour Organization. 2011;1–41.

38. Tupan. Penularan Dan Pencegahan Aids Di Indonesia.1996;21(5):2–7.
39. PPN/Bappenas K. Informasi Dasar HIV & AIDS. 2017. 1–26 p.
40. Gunung IK, Sumantera IG, Sawitri AA, Wirawan DN. Buku Pegangan Konselor HIV / AIDS. In Australia: Macfarlane Burnet Institute for Medical Research and Public Health Limited; 2003. p. 306.
41. Ditjen PP&PL Kemenkes RI. Pedoman Nasional Perawatan, Dukungan, dan Pengobatan bagi ODHA. 2003.
42. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2004 Tentang Pedoman Antiretroviral. Kementerian Kesehat Republik Indonesia. 2014;75–6.
43. Purnamawati D. Pendidikan Kesehatan HIV dan AIDS Bagi Tenaga Kesehatan. STIKes Kharisma Karawang. 2016. 88 p.
44. Kebede A, Tessema F, Bekele G, Kura Z, Merga H. Epidemiology of survival pattern and its predictors among HIV positive patients on highly active antiretroviral therapy in Southern Ethiopia public health facilities: A retrospective cohort study. *AIDS Res Ther.* 2020;17(1):1–8.
45. Abuto W, Abera A, Gobena T, Dingeta T, Markos M. Survival and predictors of mortality among HIV positive adult patients on highly active antiretroviral therapy in public hospitals of Kambata Tambaro zone, southern Ethiopia: A retrospective cohort study. *HIV/AIDS - Res Palliat Care.* 2021;13:271–81.
46. Sri Utami. Prediktor Kematian Pasien HIV-AIDS dengan Terapi ARV di RSUD Badung Bali Periode 2006 - 2014. Universitas Udayana; 2015.
47. Gayatri D. Mengenal Analisis Ketahanan (Survival Analysis). *J Keperawatan Indones.* 2014;9(1):36–40.
48. Schober P, Vetter TR. Survival analysis and interpretation of time-to-event data: The tortoise and the hare. *Anesth Analg.* 2018;127(3):792–8.
49. Suartini RSR. Analisis Survival Terhadap Ketahanan Hidup Pasien AIDS di Rumah Sakit Ketergantungan Obat Jakarta Tahun 2005-2008. Universitas Indonesia; 2008.
50. Ke S, Fang Q, Lan J, Qiao N, Zhang X, Xie C, et al. Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China. *BMC Public Health.* 2023;23(1):1–10.
51. Hodgkinson LM, Abwalaba RA, Arudo J, Margulies. B. Ten-year survival with analysis of gender difference, risk factors, and causes of death during 13 years of public antiretroviral therapy in rural Kenya. *Med (United States).*

2020;99(21):E20328.

52. Apeagee B, Agada PO, Dzaar DA, Ede AA. Application of Cox Proportional Hazards Model in Time To Event Analysis of Hiv/Aids Patients. *Fudma J Sci.* 2020;4(3):185–91.
53. Moran JA, Turner SR, Marsden MD. Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches. *Front Immunol.* 2022;13(May):1–8.
54. Kebebew K, Wencheke E. Survival analysis of HIV-infected patients under antiretroviral treatment at the Armed Forces General Teaching Hospital, Addis Ababa, Ethiopia. *Ethiop J Heal Dev.* 2012;26(3):3–7.
55. Adiningsih S. CD4+ dan Faktor yang Memengaruhi Kepatuhan Terapi Antiretroviral pada Orang dengan HIV/AIDS di Jayapura. *Bul Penelit Kesehat.* 2018;46(2):87–96.
56. Budi DW, Rahayu R. Analysis of Factors Affecting CD4+ Increase in HIV/AIDS Patients Receiving ARV Therapy. *Perspect J.* 2021;6(2).
57. Singgih NW. Analisis Ketahanan Hidup 9 Tahun Pasien HIV/AIDS Yang Mendapat Terapi Antiretroviral (ARV) Berdasarkan Cara Penularan Di Rs Kanker Dharmais Jakarta (Analisis Data Rekam Medis Rs Kanker Dharmais Jakarta). *J Inohim.* 2014;2(September 2006):100–13.
58. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: A retrospective cohort study. *AIDS Res Ther.* 2012;9:1–7.
59. Kusumaadhi ZM, Farhanah N, Udji Sofro MA. Risk Factors for Mortality among HIV/AIDS Patients. *Diponegoro Int Med J.* 2021;2(1):20–19.
60. Luvanda HB, Mukyanuzi EN, Akarro RRJ. A joint survival model for estimating the association between viral load outcome and survival time to death among HIV/AIDS patients attending health care and treatment centers in Tanzania. *BMC Public Health.* 2023;23(1):1–7.
61. Arnaot RA, Lloyd AL, O'Brien TR, Goedert JJ, Leonard JM, Nowak MA. A simple relationship between viral load and survival time in HIV-1 infection. *Proc Natl Acad Sci U S A.* 1999;96(20):11549–53.
62. Framasari DA, Flora R, Sitorus RJ. Infeksi Oportunistik Pada Odha (Orang Denagn Hiv/Aids) Terhadap Kepatuhan Minum Arv (Anti Retroviral) Di Kota Palembang. *Jambi Med J “Jurnal Kedokteran dan Kesehatan.”* 2020;8(1):67–74.
63. Nyoman L, Wisma A, Suryana K. Spectrum of Opportunistic Infection

Within Clients in Merpati Clinic Wangaya Hospital Period January - February 2014. 2014;(February):1–7.

64. Nainggolan O, Sasmitae L, Widayati R. Pengaruh Lama Terapi Antiretroviral (ARV) Terhadap Jumlah CD4 pada Penderita HIV di Rumah Sakit Umum Daerah dr. Doris Sylvanus. 2023;32(4):228–32.
65. Gultom R, Medan UI, Info A, Therapy T. Evaluasi Pola Terapi Pengobatan Penyakit- Penyakit Penyerta (Komorbid) Pada Pasien Hiv / Aids Di Ruang Rawat Inap Rumah Sakit. 2022;6(1):1–10.
66. Annisa R. Analisis Ketahanan Hidup Pasien HIV/AIDS Rawat Inap di RSUD Raden Mattaher Jambi Tahun 2016-2021. Universitas Andalas; 2023.
67. Chakravarty J, Tiwary NK, Prasad SR, Shukla S, Tiwari A, Mishra RN, et al. Determinants of survival in adult HIV patients on antiretroviral therapy in eastern Uttar Pradesh: A prospective study. *Indian J Med Res.* 2014;140(October):491–500.
68. Deres G, Nigussie ZM, Chanie MG, Worku N. Survival time and associated factors among adults living with hiv after initiation of haart in south gondar, northwest ethiopia: A retrospective cohort. *J Multidiscip Healthc.* 2021;14:1463–74.
69. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV [Internet]. Department of Health and Human Services; [cited 2024 Feb 20]. p. 1–607. Available from: <https://clinicalinfo.hiv.gov/>
70. H D, R B, Wood M. Antiretroviral Medications and Initial Therapy [Internet]. National HIV Curriculum. 2023. 36 p.
71. Severe P, Juste MA, Ambroise A, Eliacin L. Early Versus Standard Antiretroviral Therapy for HIV Infected Adults in Haiti. *N Engl J Med.* 2015;363(3):257–65.
72. Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, et al. AIDS-related Kaposi's sarcoma: Evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group staging system in the Haart era - The Italian Cooperative Group on AIDS and tumors and the Italian cohort of patients naïve from . *J Clin Oncol.* 2003;21(15):2876–82.
73. Rahmanika Fisy Aprilia; Purnami Santi Wulan; Kusumawardani Nurcahyati Akbar. Analisis Kurva Survival Kaplan Meier pada Pasien HIV/AIDS dengan Antiretroviral Therapy (ART) di RSUD Prof. Dr. Soekandar Kabupaten Mojokerto Menggunakan Uji Log Rank Fisy. *J Siains dan Seni ITS.* 2016;5(1):2337–3520.

74. RSUP Dr M Djamil Padang. Profil RSUP Dr M Djamil [Internet]. [cited 2024 Jul 22]. Available from: <https://rsdjamil.co.id/profil/>
75. Sri Rahmi Suartini. Analisis Survival Terhadap Ketahanan Hidup Pasien AIDS di Rumah Sakit Ketergantungan Obat Jakarta Tahun 2005-2008. FKM UI, 2008.
76. Carvour ML, Harms JP, Lynch CF, Mayer RR, Meier JL, Liu D, et al. Differential survival for men and women with HIV/AIDS-related neurologic diagnoses. *PLoS One*. 2015;10(6):1–11.
77. Roomaney RA, van Wyk B, Wyk VP Van. Aging with HIV: Increased Risk of HIV Comorbidities in Older Adults. *Int J Environ Res Public Health*. 2022;19(4).
78. Puspitasari E, Yuniastuti E, Rengganis I, Rumende CM. Prediktor Mortalitas Pasien HIV/AIDS Rawat Inap. *J Penyakit Dalam Indones*. 2016;3(1):22.
79. Zhao Y, Wu Z, McGoogan JM, Sha Y, Zhao D, Ma Y, et al. Nationwide cohort study of antiretroviral therapy timing: Treatment dropout and virological failure in China, 2011-2015. *Clin Infect Dis*. 2019;68(1):43–50.
80. To W, Consortium S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet*. 2009;373(9672):1352–63.
81. Dzinza R, Ngwira A. Comparing parametric and Cox regression models using HIV/AIDS survival data from a retrospective study in Ntcheu district in Malawi. *J Public health Res*. 2022;11(3):227990362211253.
82. Mageda K, Leyna GH, Mmbaga EJ. High initial HIV/AIDS-Related mortality and -its predictors among patients on antiretroviral therapy in the kagera region of Tanzania: A five-year retrospective cohort study. *AIDS Res Treat*. 2012;2012.
83. Tepungipame AT, Tonen-Wolyec S, Kalla GC, Longembe EB, Atike RO, Likwela JL, et al. Predictors of AIDS-related death among adult HIV-infected inpatients in Kisangani, the Democratic Republic of Congo. *Pan Afr Med J*. 2020;37:1–14.
84. Lorenc A, Ananthavarathan P, Lorigan J, Banarsee R, Jowata M, Brook G. The prevalence of comorbidities among people living with hiv in brent: A diverse London Borough. *London J Prim Care (Abingdon)*. 2014;6(4):84–90.
85. Bhatta L, Klouman E, Deuba K, Shrestha R, Karki DK, Ekstrom AM, et al. Survival on antiretroviral treatment among adult HIV-infected patients in

Nepal: A retrospective cohort study in far-western Region, 2006-2011. *BMC Infect Dis.* 2013;13(1).

86. Kunutsor S, Walley J, Katabira E, Muchuro S, Balidawa H, Namagala E, et al. Clinic attendance for medication refills and medication adherence amongst an antiretroviral treatment cohort in Uganda: A prospective study. *AIDS Res Treat.* 2010;2010.
87. Arizwansyah, Dessy Hermawan LS. Dukungan Keluarga Terhadap Kepatuhan Mengambil Obat ARV Pada ODHA di Puskesmas Sukaraja Kota Bandar Lampung. *Malahayati Nurs J.* 2023;5:616–32.
88. Kahana SY, Rohan J, Allison S, Frazier TW, Drotar D. A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults. *AIDS Behav.* 2013;17(1):41–60.
89. Ali H, Zakar R, Junaid K, Khan A, Fischer F. Frequency and reasons for delayed treatment initiation after HIV diagnosis: cross-sectional study in Lahore, Pakistan. *BMC Public Health.* 2021;21(1):1–12.
90. Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, et al. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. *J Int AIDS Soc.* 2014;17:1–8.
91. Grinsztejn B, Hosseinipour MC, Ribaud HJ, Swindells S, Chen YQ, Wang L, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis.* 2014;14(4):281–90.

